{"success":true,"data":{"pressRelease":{"id":"166881","rtpr_id":"nPn9Ssr3fa-20261013","ticker":"GUTS","exchange":"NASDAQ","all_tickers":["GUTS"],"title":"Robbins LLP Reminds Fractyl Health, Inc. Stockholders of the October 20, 2026 Lead Plaintiff Deadline - GUTS Investors Should Contact the Firm for Information About Leading the Class Action","author":"PR Newswire","published_at":"2026-10-13T01:59:00.221Z","article_body":"Robbins LLP Reminds Fractyl Health, Inc. Stockholders of the October 20, 2026 Lead Plaintiff Deadline - GUTS Investors Should Contact the Firm for Information About Leading the Class Action\nPR Newswire\n\nSAN DIEGO, Oct. 12, 2026\n\nSAN DIEGO, Oct. 12, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins\nLLP\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4796163-1&h=1157384292&u=https%3A%2F%2Frobbinsllp.com%2Ffractyl-health-inc%2F&a=Robbins+LLP)\n reminds investors that a class action was filed on behalf of all persons and\nentities who purchased or otherwise acquired Fractyl Health, Inc. (NASDAQ:\nGUTS) securities between January 13, 2025 and January 29, 2026 (the \"Class\nPeriod\"). Fractyl is a metabolic therapeutics company that develops therapies\nfor the treatment of type 2 diabetes (\"T2D\") and obesity.\n\nThe lawsuit centers on the Company's Revita DMR System, an investigational\ntherapy intended to treat Type 2 diabetes and obesity.\n\nIf you incurred significant losses during the Class Period and wish to seek\nappointment as lead plaintiff you should contact\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4796163-1&h=3351247205&u=https%3A%2F%2Frobbinsllp.com%2Ffractyl-health-inc%2F&a=contact)\n Robbins LLP prior to the October 20, 2026 lead plaintiff deadline.\n\nWhy Was Fractyl Health Sued?\n\nAccording to the complaint, Fractyl is developing the Revita DMR System\n(\"Revita\"), an outpatient procedural therapy designed to durably modify\nduodenal dysfunction, a pathologic consequence of a high fat and high sugar\ndiet.\n\nThe complaint alleges that during the Class Period, defendants failed to\ndisclose that:\n\n(i) Revita was less effective than defendants had led investors to believe,\nand/or operational issues at one or more of the REMAIN-1 Midpoint Cohort's\nclinical sites compromised the integrity of its efficacy results;\n(ii) accordingly, Revita's clinical, regulatory, and commercial prospects\nwere overstated, as was the REMAIN-1 Midpoint Cohort's ability to assess\nRevita's efficacy; and\n(iii) as a result, defendants' public statements were materially false and\nmisleading at all relevant times.\n\nWhy Did Fractyl Health's Stock Drop?\n\nPlaintiff alleges that on January 29, 2026, during pre-market hours, Fractyl\nissued a press release announcing six-month data from the REMAIN-1 Midpoint\nCohort.\n\nThe press release disclosed, in relevant part, that \"[a]cross the prespecified\nefficacy population ... , Revita-treated patients experienced a 4.5% weight\nregain vs 7.5% in the sham arm at 6 months\", representing a significantly more\nmodest efficacy result than previously disclosed results and falling short of\ninvestor expectations, while stating that \"[t]he Midpoint Cohort was not\ndesigned to be sufficiently powered for efficacy analysis[.]\"\n\nThe same day, also during pre-market hours, Fractyl hosted a conference call\nwith investors and analysts to discuss the six-month data from the REMAIN-1\nMidpoint Cohort. During the call, Fractyl's CEO defendant Harith Rajagopalan\nindicated that issues at one of the REMAIN-1 Midpoint Cohort study sites,\nwhich \"had higher-than-expected regain across both arms,\" were at least partly\nto blame for the cohort's disappointing six-month efficacy results.\n\nFollowing these disclosures, Fractyl's stock price fell $1.245 per share, or\n68.03%, to close at $0.585 per share on January 29, 2026.\n\nOn the same day, during post-market hours Morgan Stanley downgraded the stock\nto an \"Equal-weight\" from \"Overweight\" rating and cut its target price on the\nCompany's stock to $2.00 from $8.00.\n\nOn this news, Fractyl's stock fell another 21.7%, to close at $0.46 per share\non January 30, 2026.\n\nWho Can Participate in the Fractyl Health Class Action?\n\nThe lawsuit seeks to represent investors who purchased or otherwise acquired\nFractyl Health securities between January 13, 2025 and January 29, 2026.\nInvestors who suffered losses during that period may have legal rights under\nthe federal securities laws.\n\nWhat Is a Lead Plaintiff?\n\nThe lead plaintiff is a court-appointed investor who represents the interests\nof all class members throughout the litigation. Shareholders who wish to lead\nthe case should contact Robbins LLP before October 20, 2026.\n\nServing as lead plaintiff is not required to share in any potential recovery.\nInvestors who do not seek appointment may remain absent class members if the\ncase proceeds and later resolves successfully.\n\nDoes It Cost Anything to Participate?\n\nNo. Robbins LLP represents investors on a contingency fee basis.\n\nContact Robbins LLP\n\nInvestors seeking additional information about the Fractyl Health Inc.\nsecurities class action may contact Robbins LLP by submitting\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4796163-1&h=1218951608&u=https%3A%2F%2Frobbinsllp.com%2Ffractyl-health-inc%2F&a=submitting)\n an inquiry, emailing (mailto:adumas@robbinsllp.com)  attorney Aaron Dumas,\nJr., or calling (800) 350-6003.\n\nWhy Robbins LLP?\n\nRobbins LLP\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4796163-1&h=266038210&u=https%3A%2F%2Frobbinsllp.com%2F&a=Robbins+LLP)\n is a shareholder rights law firm focused on representing investors in\nsecurities fraud and shareholder litigation. The firm has helped recover more\nthan $2 billion for investors, obtained significant corporate governance\nreforms, and has represented shareholders in cases involving alleged\nviolations of the federal securities laws.\n\n\"Companies have an obligation to provide investors with complete and accurate\ninformation so that markets can function fairly and efficiently,\" said Brian\nJ. Robbins, Founding Partner of Robbins LLP.\n\nTo be notified if a class action against Fractyl Health Inc. settles or to\nreceive free alerts when corporate executives engage in wrongdoing, sign up\nfor Stock Watch\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4796163-1&h=2831221116&u=https%3A%2F%2Frobbinsllp.com%2Fstock-watch%2F&a=Stock+Watch)\n today.\n\nAttorney Advertising.  Past results do not guarantee a similar outcome.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/robbins-llp-reminds-fractyl-health-inc-stockholders-of-the-october-20-2026-lead-plaintiff-deadline---guts-investors-should-contact-the-firm-for-information-about-leading-the-class-action-302906243.html\n(https://www.prnewswire.com/news-releases/robbins-llp-reminds-fractyl-health-inc-stockholders-of-the-october-20-2026-lead-plaintiff-deadline---guts-investors-should-contact-the-firm-for-information-about-leading-the-class-action-302906243.html)\n\nSOURCE Robbins LLP\n\n\n\nAaron Dumas, Jr., Robbins LLP, 5060 Shoreham Pl., Ste. 300, San Diego, CA 92122, adumas@robbinsllp.com, (800) 350-6003, www.robbinsllp.com\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS559099/Robbins-LLP-Logo.jpg?id=OA3014386\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn9Ssr3fa-20261013","title":"Robbins LLP Reminds Fractyl Health, Inc. Stockholders of the October 20, 2026 Lead Plaintiff Deadline - GUTS Investors Should Contact the Firm for Information About Leading the Class Action","author":"PR Newswire","ticker":"GUTS","created":"2026-10-13T01:59:00.221Z","tickers":["GUTS"],"exchange":"NASDAQ","article_body":"Robbins LLP Reminds Fractyl Health, Inc. Stockholders of the October 20, 2026 Lead Plaintiff Deadline - GUTS Investors Should Contact the Firm for Information About Leading the Class Action\nPR Newswire\n\nSAN DIEGO, Oct. 12, 2026\n\nSAN DIEGO, Oct. 12, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins\nLLP\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4796163-1&h=1157384292&u=https%3A%2F%2Frobbinsllp.com%2Ffractyl-health-inc%2F&a=Robbins+LLP)\n reminds investors that a class action was filed on behalf of all persons and\nentities who purchased or otherwise acquired Fractyl Health, Inc. (NASDAQ:\nGUTS) securities between January 13, 2025 and January 29, 2026 (the \"Class\nPeriod\"). Fractyl is a metabolic therapeutics company that develops therapies\nfor the treatment of type 2 diabetes (\"T2D\") and obesity.\n\nThe lawsuit centers on the Company's Revita DMR System, an investigational\ntherapy intended to treat Type 2 diabetes and obesity.\n\nIf you incurred significant losses during the Class Period and wish to seek\nappointment as lead plaintiff you should contact\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4796163-1&h=3351247205&u=https%3A%2F%2Frobbinsllp.com%2Ffractyl-health-inc%2F&a=contact)\n Robbins LLP prior to the October 20, 2026 lead plaintiff deadline.\n\nWhy Was Fractyl Health Sued?\n\nAccording to the complaint, Fractyl is developing the Revita DMR System\n(\"Revita\"), an outpatient procedural therapy designed to durably modify\nduodenal dysfunction, a pathologic consequence of a high fat and high sugar\ndiet.\n\nThe complaint alleges that during the Class Period, defendants failed to\ndisclose that:\n\n(i) Revita was less effective than defendants had led investors to believe,\nand/or operational issues at one or more of the REMAIN-1 Midpoint Cohort's\nclinical sites compromised the integrity of its efficacy results;\n(ii) accordingly, Revita's clinical, regulatory, and commercial prospects\nwere overstated, as was the REMAIN-1 Midpoint Cohort's ability to assess\nRevita's efficacy; and\n(iii) as a result, defendants' public statements were materially false and\nmisleading at all relevant times.\n\nWhy Did Fractyl Health's Stock Drop?\n\nPlaintiff alleges that on January 29, 2026, during pre-market hours, Fractyl\nissued a press release announcing six-month data from the REMAIN-1 Midpoint\nCohort.\n\nThe press release disclosed, in relevant part, that \"[a]cross the prespecified\nefficacy population ... , Revita-treated patients experienced a 4.5% weight\nregain vs 7.5% in the sham arm at 6 months\", representing a significantly more\nmodest efficacy result than previously disclosed results and falling short of\ninvestor expectations, while stating that \"[t]he Midpoint Cohort was not\ndesigned to be sufficiently powered for efficacy analysis[.]\"\n\nThe same day, also during pre-market hours, Fractyl hosted a conference call\nwith investors and analysts to discuss the six-month data from the REMAIN-1\nMidpoint Cohort. During the call, Fractyl's CEO defendant Harith Rajagopalan\nindicated that issues at one of the REMAIN-1 Midpoint Cohort study sites,\nwhich \"had higher-than-expected regain across both arms,\" were at least partly\nto blame for the cohort's disappointing six-month efficacy results.\n\nFollowing these disclosures, Fractyl's stock price fell $1.245 per share, or\n68.03%, to close at $0.585 per share on January 29, 2026.\n\nOn the same day, during post-market hours Morgan Stanley downgraded the stock\nto an \"Equal-weight\" from \"Overweight\" rating and cut its target price on the\nCompany's stock to $2.00 from $8.00.\n\nOn this news, Fractyl's stock fell another 21.7%, to close at $0.46 per share\non January 30, 2026.\n\nWho Can Participate in the Fractyl Health Class Action?\n\nThe lawsuit seeks to represent investors who purchased or otherwise acquired\nFractyl Health securities between January 13, 2025 and January 29, 2026.\nInvestors who suffered losses during that period may have legal rights under\nthe federal securities laws.\n\nWhat Is a Lead Plaintiff?\n\nThe lead plaintiff is a court-appointed investor who represents the interests\nof all class members throughout the litigation. Shareholders who wish to lead\nthe case should contact Robbins LLP before October 20, 2026.\n\nServing as lead plaintiff is not required to share in any potential recovery.\nInvestors who do not seek appointment may remain absent class members if the\ncase proceeds and later resolves successfully.\n\nDoes It Cost Anything to Participate?\n\nNo. Robbins LLP represents investors on a contingency fee basis.\n\nContact Robbins LLP\n\nInvestors seeking additional information about the Fractyl Health Inc.\nsecurities class action may contact Robbins LLP by submitting\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4796163-1&h=1218951608&u=https%3A%2F%2Frobbinsllp.com%2Ffractyl-health-inc%2F&a=submitting)\n an inquiry, emailing (mailto:adumas@robbinsllp.com)  attorney Aaron Dumas,\nJr., or calling (800) 350-6003.\n\nWhy Robbins LLP?\n\nRobbins LLP\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4796163-1&h=266038210&u=https%3A%2F%2Frobbinsllp.com%2F&a=Robbins+LLP)\n is a shareholder rights law firm focused on representing investors in\nsecurities fraud and shareholder litigation. The firm has helped recover more\nthan $2 billion for investors, obtained significant corporate governance\nreforms, and has represented shareholders in cases involving alleged\nviolations of the federal securities laws.\n\n\"Companies have an obligation to provide investors with complete and accurate\ninformation so that markets can function fairly and efficiently,\" said Brian\nJ. Robbins, Founding Partner of Robbins LLP.\n\nTo be notified if a class action against Fractyl Health Inc. settles or to\nreceive free alerts when corporate executives engage in wrongdoing, sign up\nfor Stock Watch\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4796163-1&h=2831221116&u=https%3A%2F%2Frobbinsllp.com%2Fstock-watch%2F&a=Stock+Watch)\n today.\n\nAttorney Advertising.  Past results do not guarantee a similar outcome.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/robbins-llp-reminds-fractyl-health-inc-stockholders-of-the-october-20-2026-lead-plaintiff-deadline---guts-investors-should-contact-the-firm-for-information-about-leading-the-class-action-302906243.html\n(https://www.prnewswire.com/news-releases/robbins-llp-reminds-fractyl-health-inc-stockholders-of-the-october-20-2026-lead-plaintiff-deadline---guts-investors-should-contact-the-firm-for-information-about-leading-the-class-action-302906243.html)\n\nSOURCE Robbins LLP\n\n\n\nAaron Dumas, Jr., Robbins LLP, 5060 Shoreham Pl., Ste. 300, San Diego, CA 92122, adumas@robbinsllp.com, (800) 350-6003, www.robbinsllp.com\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS559099/Robbins-LLP-Logo.jpg?id=OA3014386\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-10-13T01:59:00.269770805Z","server_sent_at_ms":1791856740269},"received_at":"2026-10-13T01:59:00.321Z","source_url":"https://www.prnewswire.com/news-releases/robbins-llp-reminds-fractyl-health-inc-stockholders-of-the-october-20-2026-lead-plaintiff-deadline---guts-investors-should-contact-the-firm-for-information-about-leading-the-class-action-302906243.html"},"analysis":{"id":"155218","press_release_id":"166881","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["pending securities class action alleging overstated Revita DMR efficacy and site-integrity issues in the REMAIN-1 trial","stock previously fell 68% on disappointing REMAIN-1 Midpoint Cohort data and now trades near $0.46"],"eventType":"legal_litigation","narrative":"Robbins LLP issued a shareholder-solicitation notice reminding Fractyl Health (GUTS) investors of the October 20, 2026 lead plaintiff deadline in an already-filed securities class action covering purchases between January 13, 2025 and January 29, 2026.\n\nThe underlying complaint alleges the company overstated the efficacy of the Revita DMR System, citing site-integrity issues at the REMAIN-1 Midpoint Cohort; the stock fell 68% to $0.585 after the January 29 six-month data disclosure.\n\nThis release is law-firm marketing tied to a prior event, not a new disclosure from Fractyl itself; treat as low-signal noise.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm deadline reminder tied to a previously reported stock collapse -- suppress."},"keyFigures":{},"namedEntities":{"people":[{"name":"Harith Rajagopalan","role":"CEO and named defendant"},{"name":"Aaron Dumas, Jr.","role":"attorney, Robbins LLP"},{"name":"Brian J. Robbins","role":"Founding Partner, Robbins LLP"}],"products":["Revita DMR System"],"companies":[{"name":"Fractyl Health, Inc.","ticker":"GUTS","relationship":"class action target"},{"name":"Robbins LLP","relationship":"plaintiff law firm"},{"name":"Morgan Stanley","relationship":"mentioned"}],"dollarAmounts":[{"amount":"$1.245","context":"per-share stock price decline on January 29, 2026"},{"amount":"$0.585","context":"closing price on January 29, 2026"},{"amount":"$2.00","context":"Morgan Stanley reduced price target"},{"amount":"$8.00","context":"prior Morgan Stanley price target"},{"amount":"$0.46","context":"closing price on January 30, 2026"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm solicitation by Robbins LLP reminding stockholders of an existing class action's lead plaintiff deadline. No new issuer disclosure, no certified class, and no settlement announced."},"tickerRelevance":{"others":[],"primary":"GUTS"},"globalImportance":12,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Robbins LLP issued a shareholder-solicitation notice reminding Fractyl Health (GUTS) investors of the October 20, 2026 lead plaintiff deadline in an already-filed securities class action covering purchases between January 13, 2025 and January 29, 2026.\n\nThe underlying complaint alleges the company overstated the efficacy of the Revita DMR System, citing site-integrity issues at the REMAIN-1 Midpoint Cohort; the stock fell 68% to $0.585 after the January 29 six-month data disclosure.\n\nThis release is law-firm marketing tied to a prior event, not a new disclosure from Fractyl itself; treat as low-signal noise.","key_figures":{},"named_entities":{"people":[{"name":"Harith Rajagopalan","role":"CEO and named defendant"},{"name":"Aaron Dumas, Jr.","role":"attorney, Robbins LLP"},{"name":"Brian J. Robbins","role":"Founding Partner, Robbins LLP"}],"products":["Revita DMR System"],"companies":[{"name":"Fractyl Health, Inc.","ticker":"GUTS","relationship":"class action target"},{"name":"Robbins LLP","relationship":"plaintiff law firm"},{"name":"Morgan Stanley","relationship":"mentioned"}],"dollarAmounts":[{"amount":"$1.245","context":"per-share stock price decline on January 29, 2026"},{"amount":"$0.585","context":"closing price on January 29, 2026"},{"amount":"$2.00","context":"Morgan Stanley reduced price target"},{"amount":"$8.00","context":"prior Morgan Stanley price target"},{"amount":"$0.46","context":"closing price on January 30, 2026"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-13T01:59:06.494Z","global_importance":12,"audience_relevance":10,"importance_components":{"tickerTier":"micro-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":6166,"modelName":"glm-5.3-flashx"}}